- In August 2023, Pfizer Inc. (U.S.) received U.S. FDA approval for ABRYSVO, its bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. This significant approval marked a new era in maternal immunization and is expected to contribute to the adult vaccine segment, which accounted for a dominant share of the vaccines market in 2023
- In May 2023, GSK plc (U.K.) received U.S. FDA approval for Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This was the first RSV vaccine approved for older adults, addressing a major unmet medical need and is set to significantly impact the adult vaccine market
- In October 2023, Lonza (Switzerland) announced an expanded collaboration with Vaxcyte for the global commercial manufacturing of broad-spectrum pneumococcal conjugate vaccines. This highlights Lonza's role as a key CDMO (Contract Development and Manufacturing Organization) in the vaccine market, supporting the production of crucial vaccines. The CDMO market segment is experiencing growth as more companies outsource complex manufacturing
- In January 2023, Sanofi (France), as part of its ongoing R&D efforts, continued to progress its vaccine pipeline. While specific product launches with percentages in January 2023 are not widely reported for the "Vaccine Production" aspect, Sanofi's commitment to vaccine innovation remains strong, with developments in areas such as influenza and RSV. For instance, Sanofi, in collaboration with AstraZeneca, later in 2023 (and accelerated in 2024 for 2025 season) significantly increased production capacity for Beyfortus (nirsevimab), an RSV immunization for infants, underscoring their dedication to meeting growing demand in key disease areas
